Table 2.
Patient percentage with undetectable HCV-RNA over the time.
| % (n) | HCV-RNA <12 IU/mL | HCV-RNA ≥12 IU/mL | No record |
|---|---|---|---|
| All patients | |||
| Baseline (n=104) | 0.0% (0) | 100% (104) | 0.0% (0) |
| Month 1 (n=104) | 51.9% (54) | 36.5% (38) | 11.5% (12) |
| Month 3 (n=100) | 23.0% (23) | 4.0% (4) | 7.03% (73) |
| Treatment-end (n=99) | 77.8% (77) | 1.0% (1) | 21.2% (21) |
| SVR12 (n=95) | 98.9% (94) | 1.1% (1) | 0.0% (0) |
| Treatment experienced | |||
| Baseline (n=79) | 0.0% (0) | 100% (79) | 0.0% (0) |
| Month 1 (n=79) | 55.7% (44) | 35.4% (28) | 8.9% (7) |
| Month 3 (n=79) | 22.8% (18) | 3.8% (3) | 73.4% (58) |
| Treatment-end (n=78) | 80.8% (63) | 0.0% (0) | 19.2% (15) |
| SVR12 (n=77) | 100% (77) | 0.0% (0) | 0.0% (0) |
| Treatment naïve | |||
| Baseline (n=25) | 0.0% (0) | 100% (25) | 0.0% (0) |
| Month 1 (n=25) | 40.0% (10) | 40.0% (10) | 20.0% (5) |
| Month 3 (n=21) | 23.8% (5) | 4.8% (1) | 71.4% (15) |
| Treatment-end (n=21) | 66.7% (14) | 4.8% (1) | 28.6% (6) |
| SVR12 (n=18) | 94.4% (17) | 5.6% (1) | 0.0% (0) |
SVR12: sustained virologic response at 12 weeks after treatment-end.